Cytokine Inhibition in Hepatocellular Carcinoma

Project: Research project

Project Details

Description

DESCRIPTION (provided by applicant): The candidate is a Clinical Assistant
Professor in the divisions of Medical Oncology and Hematology in the
Department of Medicine at The Mount Sinai School of Medicine. He is also
Co-Director of the Hematology-Oncology Fellowship. He will pursue career
development in the responsible conduct of clinical research while planning and
conducting preliminary trials and translational research for patients with
unresectable hepatocellular carcinoma. The plans for career development
include participation in research methodology courses through the
institution's K30 award (Principal Investigator, Janice Gabrilove, M.D.,
Division Chief in Medical Oncology), ongoing participation in clinical
investigation, multi disciplinary care of patients with liver diseases and
hepatobiliary malignancies, and mentorship by faculty with proven
investigative and training capabilities in Clinical Oncology, Liver Diseases,
and translational research (including Janice Gabrilove, M.D., Scott Friedman,
M.D.). The cytokines basic fibroblast growth factor (bFGF), insulin-like
growth factor II (IGF-II), transforming growth factor-alpha (TGF-alpha),
vascular endothelial growth factor (VEGF) and the process of neoangiogenesis
have been shown to play a critical role in the pathogenesis of hepatocellular
carcinoma. Outlined in this application, the research plan is based upon the
hypothesis that inhibition of cytokine-mediated tumor cell survival and
growth, and inhibition of neoangiogenesis, are likely to be of clinical
utility. Inhibitors of specific cytokines and their receptors are currently
available for evaluation as therapeutic agents for this disease in which these
specific biological processes have been shown to play a critical role in
pathogenesis, evolution and progression. Given the institutional strength as
a center of excellence in liver disease and liver transplantation, the support
of outstanding mentors, strong institutional resources for clinical
investigation, an intense didactic curriculum in clinical research, and the
candidate's potential for developing multi disciplinary clinical research, it
is highly likely that the five-year training period will enable the candidate
to emerge as an innovative, disciplined clinical and translational
investigator, with a focus on the development of novel therapeutic strategies
in hepatobiliary malignancies.
StatusFinished
Effective start/end date5/1/034/30/04

Funding

  • National Cancer Institute: $133,731.00

ASJC

  • Drug Discovery
  • Medical Laboratory Technology
  • Molecular Medicine
  • Oncology
  • Hepatology

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.